|
|
|
|
|
|
|
|
|
17.04.25 - 08:06
|
Fresenius Medical Care (FMC) St Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für FMC mit einem Kursziel von 41,50 Euro auf "Underweight" belassen. Die Volumina dürften im ersten Quartal erwartungsgemäß schwach gewesen sein, schrieb Analyst David Adlington am ......
|
|
|
16.04.25 - 19:48
|
Fresenius Medical Care (FMC) St Market-Perform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Fresenius Medical Care (FMC) auf "Market-Perform" mit einem Kursziel von 50 Euro belassen. Der Dialyseanbieter habe vor der "Quiet Period" im Vorfeld der Quartalszahlen ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.03.25 - 12:06
|
Diality Names Dr. Chris Springer to Board of Directors (Business Wire)
|
|
|
IRVINE, Calif.--(BUSINESS WIRE)--#leadership--Diality Inc., a medical device company that has developed the Moda-flx Hemodialysis System™, today announced the addition of Dr. Chris Springer to its board of directors.
Dr. Springer brings 30 years of commercial and strategic experience in the pharmaceutical and biotech industries to Diality. As Chief Strategy Officer for Vifor Pharma, he created a joint renal-drug company between Vifor Pharmaceuticals and Fresenius Medical Care as well as oversaw a series of licensing deals and acquisitions, culminating in the acquisition of Vifor Pharma by CSL for $11.7B. Prior to Vifor Pharma, Springer also spent time in executive roles with Amgen. He sits on the board of multiple biotech firms, including Adrenomed, Nagi Bioscience, Quercis Pharma and HICT.
“Chris's commercial experience and strategic focus is exactly what Diality needs as we transition to the early stages of commercialization of the Moda-flx Hemodialysis System,” said Osman Khawar, MD, CEO of Dial...
|
|
|
|
|
21.03.25 - 09:06
|
Fresenius Medical Care (FMC) St Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für FMC nach Jahreszahlen von 33 auf 37 Euro angehoben, aber die Einstufung auf "Underperform" belassen. Analyst James Vane-Tempest passte in einer am Freitag vorliegenden Studie ......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
